Skip to content

Study · Non-randomized trial · n = 13 · 1990

3 results

Desmopressin: a new principle for symptomatic treatment of urgency and incontinence in patients with multiple sclerosis.

Kinn AC, Larsson PO

Scandinavian journal of urology and nephrology1 Jan 1990Cited by 42 (Europe PMC)

PMID2192444 (opens in a new tab)DOI10.3109/00365599009180373 (opens in a new tab)PepBankPUB-02192444
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with advanced multiple sclerosis and urge incontinence, desmopressin significantly decreased micturition frequency.

    In plain wordsIn patients with advanced multiple sclerosis and urge incontinence, desmopressin significantly reduced urination frequency.

    Peptide
    Desmopressin
    Outcome
    DecreaseMicturition frequency
    Study

    n = 13

    Outcome group
    Urinary Continence · Kidney and urinary
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    p
    < 0.05
    micturition frequency

    Source sentences

    Summary
    The micturition frequency decreased significantly (p less than 0.05).
    2 context sentences
    Summary · context
    Peroral medication was favourable in these patients with muscular dysfunction.
    Summary · context
    Thirteen patients with advanced multiple sclerosis and urge urinary incontinence were treated with desmopressin--a synthetic analogue of antidiuretic hormone--in a double-blind cross-over study.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with advanced multiple sclerosis and urge incontinence, less leakage during desmopressin treatment was considered valuable for daily life.

    In plain wordsIn patients with multiple sclerosis and urge incontinence, less leakage during desmopressin treatment was considered valuable for daily life.

    Peptide
    Desmopressin
    Outcome
    DecreaseUrine leakage
    Study

    n = 13

    Outcome group
    Urinary Continence · Kidney and urinary
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    Less leakage was considered valuable for daily life.
    2 context sentences
    Summary · context
    Peroral medication was favourable in these patients with muscular dysfunction.
    Summary · context
    Thirteen patients with advanced multiple sclerosis and urge urinary incontinence were treated with desmopressin--a synthetic analogue of antidiuretic hormone--in a double-blind cross-over study.
  3. 03HumanNon-randomized trialSafety outcome

    In patients with advanced multiple sclerosis and urge incontinence, desmopressin treatment had few side effects.

    In plain wordsIn patients with advanced multiple sclerosis and urge incontinence, desmopressin treatment had few side effects.

    Peptide
    Desmopressin
    Outcome
    Not applicableSide effects
    Study

    n = 13

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    Side-effects were few.
    2 context sentences
    Summary · context
    Peroral medication was favourable in these patients with muscular dysfunction.
    Summary · context
    Thirteen patients with advanced multiple sclerosis and urge urinary incontinence were treated with desmopressin--a synthetic analogue of antidiuretic hormone--in a double-blind cross-over study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.